{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T03:55:22Z","timestamp":1790826922107,"version":"4.1.0"},"reference-count":24,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,5,12]],"date-time":"2022-05-12T00:00:00Z","timestamp":1652313600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Cell. Infect. Microbiol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Early studies showed the utility of pretransplant QuantiFERON-Cytomegalovirus (QF-CMV) assays for CMV-disease prediction post kidney transplant (KT). However, recent data are conflicting.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This prospective cohort study enrolled adult patients undergoing KT between July 2017 and May 2019. Patients with antithymocyte globulin therapy or negative pretransplant CMV IgG were excluded. QF-CMV assays were performed on transplantation day and one month thereafter, and CMV viral loads were obtained 1, 3, and 6 months posttransplantation. The primary outcome was CMV viremia within 6 months. The QF-CMV assay\u2013posttransplant CMV viremia association was analyzed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Fifty-five patients were enrolled (male, 58.2%; mean (SD) age, 46.5 (10.2) years). Fifty-two (94.5%) received CMV-seropositive donor kidneys. Over 6 months, 29 patients developed CMV viremia (52.7%), with 14 (25.5%) having significant viremia requiring antiviral therapy. The CMV-viremia incidence of patients with nonreactive and reactive baseline QF-CMV assays did not differ significantly (55.3% and 47.1%;\n                      <jats:italic>p<\/jats:italic>\n                      = 0.573). Among patients with reactive pretransplant QF-CMV assays, there was a trend toward a lower incidence of CMV viremia for those who were persistently reactive at 1 month after KTs, although there was no statistically significant difference (50% vs 83%;\n                      <jats:italic>p<\/jats:italic>\n                      = 0.132).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Our study could not support the use of single-timepoint pretransplant or 1-month posttransplant QF-CMV assays as a predictor for posttransplant CMV viremia in CMV seropositive KT recipients. Investigation of the association between dynamic QF-CMV-status changes and CMV-viremia incidence are needed.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fcimb.2022.893232","type":"journal-article","created":{"date-parts":[[2022,5,12]],"date-time":"2022-05-12T10:46:55Z","timestamp":1652352415000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":14,"title":["QuantiFERON-Cytomegalovirus Assay for Prediction of Cytomegalovirus Viremia in Kidney Transplant Recipients: Study From High Cytomegalovirus Seroprevalence Country"],"prefix":"10.3389","volume":"12","author":[{"given":"Kritsada","family":"Pongsakornkullachart","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Methee","family":"Chayakulkeeree","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Attapong","family":"Vongwiwatana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wannee","family":"Kantakamalakul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peenida","family":"Skulratanasak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pakpoom","family":"Phoompoung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,5,12]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"2501","DOI":"10.1128\/JCM.00563-13","article-title":"Comparison of Cytomegalovirus (CMV) Enzyme-Linked Immunosorbent Spot and CMV Quantiferon Gamma Interferon-Releasing Assays in Assessing Risk of CMV Infection in Kidney Transplant Recipients","volume":"51","author":"Abate","year":"2013","journal-title":"J. Clin. Microbiol."},{"key":"B2","doi-asserted-by":"publisher","first-page":"738","DOI":"10.1111\/ajt.12049","article-title":"Pretransplant Interferon-Gamma Secretion by CMV-Specific CD8+ T Cells Informs the Risk of CMV Replication After Transplantation","volume":"13","author":"Cantisan","year":"2013","journal-title":"Am. J. Transplant."},{"key":"B3","doi-asserted-by":"publisher","first-page":"2460","DOI":"10.1016\/j.transproceed.2015.08.011","article-title":"Risk Factors of Cytomegalovirus Disease in Kidney Transplant Recipients: A Single-Center Study in Thailand","volume":"47","author":"Chiasakul","year":"2015","journal-title":"Transplant. Proc."},{"key":"B4","doi-asserted-by":"publisher","first-page":"381.e1","DOI":"10.1016\/j.cmi.2018.05.010","article-title":"Regular Monitoring of Cytomegalovirus-Specific Cell-Mediated Immunity in Intermediate-Risk Kidney Transplant Recipients: Predictive Value of the Immediate Post-Transplant Assessment","volume":"25","author":"Fernandez-Ruiz","year":"2019","journal-title":"Clin. Microbiol. Infect."},{"key":"B5","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1111\/j.1399-0012.2006.00618.x","article-title":"Cytomegalovirus in Transplantation - Challenging the Status Quo","volume":"21","author":"Fishman","year":"2007","journal-title":"Clin. Transplant."},{"key":"B6","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1586\/erm.10.109","article-title":"QuantiFERON(R)-CMV Assay for the Assessment of Cytomegalovirus Cell-Mediated Immunity","volume":"11","author":"Giulieri","year":"2011","journal-title":"Expert Rev. Mol. Diagn."},{"key":"B7","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/j.jcv.2018.06.009","article-title":"T-Track-CMV and QuantiFERON-CMV Assays for Prediction of Protection From CMV Reactivation in Kidney Transplant Recipients","volume":"105","author":"Gliga","year":"2018","journal-title":"J. Clin. Virol."},{"key":"B8","doi-asserted-by":"publisher","first-page":"1228","DOI":"10.1111\/j.1600-6143.2010.03074.x","article-title":"The Efficacy and Safety of 200 Days Valganciclovir Cytomegalovirus Prophylaxis in High-Risk Kidney Transplant Recipients","volume":"10","author":"Humar","year":"2010","journal-title":"Am. J. Transplant."},{"key":"B9","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/j.jcv.2018.01.002","article-title":"Assessing the Risk of CMV Reactivation and Reconstitution of Antiviral Immune Response Post Bone Marrow Transplantation by the QuantiFERON-CMV-Assay and Real Time PCR","author":"Krawczyk","year":"2018","journal-title":"J. Clin. Virol."},{"key":"B10","doi-asserted-by":"publisher","first-page":"1214","DOI":"10.1111\/j.1600-6143.2009.02618.x","article-title":"Cell-Mediated Immunity to Predict Cytomegalovirus Disease in High-Risk Solid Organ Transplant Recipients","volume":"9","author":"Kumar","year":"2009","journal-title":"Am. J. Transplant."},{"key":"B11","doi-asserted-by":"publisher","first-page":"317","DOI":"10.4110\/in.2017.17.5.317","article-title":"Comparison of the Commercial QuantiFERON-CMV and Overlapping Peptide-Based ELISPOT Assays for Predicting CMV Infection in Kidney Transplant Recipients","volume":"17","author":"Kwon","year":"2017","journal-title":"Immune Netw."},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0189488","article-title":"Cytomegalovirus (CMV) Immune Monitoring With ELISPOT and QuantiFERON-CMV Assay in Seropositive Kidney Transplant Recipients","volume":"12","author":"Lee","year":"2017","journal-title":"PLoS One"},{"key":"B13","doi-asserted-by":"publisher","first-page":"3574","DOI":"10.1016\/j.transproceed.2010.07.101","article-title":"Quantiferon-CMV Test in Prediction of Cytomegalovirus Infection After Kidney Transplantation","volume":"42","author":"Lochmanova","year":"2010","journal-title":"Transplant. Proc."},{"key":"B14","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1097\/01.TP.0000438025.96334.eb","article-title":"Pretransplant CD8 T-Cell Response to IE-1 Discriminates Seropositive Kidney Recipients at Risk of Developing CMV Infection Posttransplant","volume":"97","author":"Lopez-Oliva","year":"2014","journal-title":"Transplantation"},{"key":"B15","doi-asserted-by":"publisher","first-page":"817","DOI":"10.1093\/cid\/cis993","article-title":"Assessment of Cytomegalovirus-Specific Cell-Mediated Immunity for the Prediction of Cytomegalovirus Disease in High-Risk Solid-Organ Transplant Recipients: A Multicenter Cohort Study","volume":"56","author":"Manuel","year":"2013","journal-title":"Clin. Infect. Dis."},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1111\/ctr.13512","article-title":"Cytomegalovirus in Solid Organ Transplant Recipients-Guidelines of the American Society of Transplantation Infectious Diseases Community of Practice","volume":"33","author":"Razonable","year":"2019","journal-title":"Clin. Transplant."},{"key":"B17","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1186\/s12879-020-4787-4","article-title":"Clinical Experience With a Novel Assay Measuring Cytomegalovirus (CMV)-Specific CD4+ and CD8+ T-Cell Immunity by Flow Cytometry and Intracellular Cytokine Staining to Predict Clinically Significant CMV Events","volume":"20","author":"Rogers","year":"2020","journal-title":"BMC Infect. Dis."},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000015228","article-title":"Diagnostic Performance of Cytomegalovirus (CMV) Immune Monitoring With ELISPOT and QuantiFERON-CMV Assay in Kidney Transplantation: A PRISMA-Compliant Article","volume":"98","author":"Ruan","year":"2019","journal-title":"Med. (Baltimore)"},{"key":"B19","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1164\/rccm.201504-0733OC","article-title":"Polyfunctional T-Cell Signatures to Predict Protection From Cytomegalovirus After Lung Transplantation","volume":"193","author":"Snyder","year":"2016","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"B20","doi-asserted-by":"publisher","first-page":"1650","DOI":"10.1016\/j.transproceed.2016.01.046","article-title":"Clinical Utility of QuantiFERON-Cytomegalovirus Test in Management of Kidney Transplant Recipients","volume":"48","author":"Tarasewicz","year":"2016","journal-title":"Transplant. Proc."},{"key":"B21","first-page":"105","article-title":"Cytokine-Mediated Induction of Endothelial Adhesion Molecule and Histocompatibility Leukocyte Antigen Expression by Cytomegalovirus-Activated T Cells","volume":"148","author":"Waldman","year":"1996","journal-title":"Am. J. Pathol."},{"key":"B22","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1111\/j.1399-3062.2006.00199.x","article-title":"Ex Vivo Monitoring of Human Cytomegalovirus-Specific CD8+ T-Cell Responses Using QuantiFERON-CMV","volume":"9","author":"Walker","year":"2007","journal-title":"Transpl Infect. Dis."},{"key":"B23","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1016\/j.transproceed.2011.12.029","article-title":"Cytomegalovirus Viremia After Kidney Transplantation in Thailand: Predictors of Symptomatic Infection and Outcome","volume":"44","author":"Watcharananan","year":"2012","journal-title":"Transplant. Proc."},{"key":"B24","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1007\/s11908-018-0610-4","article-title":"Immune Monitoring for CMV in Transplantation","volume":"20","author":"Yong","year":"2018","journal-title":"Curr. Infect. Dis. Rep."}],"container-title":["Frontiers in Cellular and Infection Microbiology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcimb.2022.893232\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,12]],"date-time":"2022-05-12T10:46:57Z","timestamp":1652352417000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcimb.2022.893232\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,12]]},"references-count":24,"alternative-id":["10.3389\/fcimb.2022.893232"],"URL":"https:\/\/doi.org\/10.3389\/fcimb.2022.893232","relation":{},"ISSN":["2235-2988"],"issn-type":[{"value":"2235-2988","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,5,12]]},"article-number":"893232"}}